Bribery and corruption in the pharma industry: what the law says
This article was originally published in Scrip
Executive Summary
A recent exposé of National Health Service (NHS) staff in the UK allegedly accepting financial inducements and lavish hospitality from pharmaceutical companies suggests that despite high-profile enforcement cases in recent years, the pharmaceutical industry still has work to do to ensure all bribery and corruption in connection with the promotion of medicinal products has been eradicated. Consequently, the industry will face increasing pressure and scrutiny to demonstrate it has robust policies in place to monitor compliance and mitigate the risk of bribery and corruption.